| P2093 | author name string | C H Wilder-Smith | |
| P2860 | cites work | Morphine intoxication in renal failure: the role of morphine-6-glucuronide | Q24537958 |
| | Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide | Q28274355 |
| | Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer | Q28331832 |
| | Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic | Q28343021 |
| | Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine | Q28609389 |
| | Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects | Q30498485 |
| | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis | Q33565994 |
| | Ulcerogenicity of piroxicam: an analysis of spontaneously reported data | Q34068129 |
| | Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy | Q34182784 |
| | Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. | Q34228651 |
| | Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states | Q34306766 |
| | Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs | Q34320726 |
| | The metabolism and bioavailability of morphine in patients with severe liver cirrhosis | Q34398339 |
| | The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive‐care patients | Q34403128 |
| | Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. | Q34459461 |
| | Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. | Q34491260 |
| | Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration | Q34527487 |
| | Renal toxicity of the nonsteroidal anti-inflammatory drugs | Q34731188 |
| | The effect of cirrhosis on the disposition and elimination of meperidine in man | Q68803776 |
| | A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms | Q69203822 |
| | Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs | Q69487191 |
| | Lack of gastric mucosal protection by sucralfate during long-term aspirin ingestion in humans | Q69509079 |
| | Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study | Q69596139 |
| | Kinetics of morphine in patients with renal failure | Q69867130 |
| | Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial | Q69927046 |
| | Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? | Q70255031 |
| | Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions--2 | Q70288264 |
| | Methadone disposition in patients with chronic liver disease | Q70904353 |
| | Normal metabolism of morphine in cirrhosis | Q70942483 |
| | Gastric tolerability of nimesulide. A double-blind comparison of 2 oral dosage regimens and placebo | Q71605023 |
| | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study | Q71658365 |
| | Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease | Q72114814 |
| | Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia | Q72400519 |
| | Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease | Q72715711 |
| | Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group | Q72764249 |
| | NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects | Q73094778 |
| | The analgesic tramadol has minimal effect on gastrointestinal motor function | Q73122863 |
| | Nonsteroidal antiinflammatory drugs, ulcers and risk:A collaborative meta-analysis | Q73502258 |
| | Pain in the oldest-old during hospitalization and up to one year later. HELP Investigators. Hospitalized Elderly Longitudinal Project | Q73785370 |
| | The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly | Q73927463 |
| | Current FDA-approved treatments for Helicobacter pylori and the FDA approval process | Q73933674 |
| | A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group | Q74288809 |
| | Utilization of nonsteroidal antiinflammatory drugs | Q93568748 |
| | Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models | Q46245351 |
| | Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity | Q46705627 |
| | The excitatory effects of opioids | Q48476946 |
| | Differing effects of pethidine and morphine on human sphincter of Oddi motility. | Q50160636 |
| | Clinical presentation of peptic ulcer in the elderly. | Q50932777 |
| | Prevalence and source of pain in pediatric inpatients. | Q50942189 |
| | Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. | Q50956118 |
| | A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. | Q50959758 |
| | Assessing pain in elderly patients who cannot respond verbally. | Q51022901 |
| | Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. | Q51057585 |
| | Dementia and response to pain in the elderly. | Q51108617 |
| | Histamine release by four narcotics: a double-blind study in humans. | Q51787849 |
| | High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. | Q51810379 |
| | The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. | Q52108062 |
| | Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs | Q58053744 |
| | Lack of Analgesic Activity of Morphine-6-glucuronide after Short-term Intravenous Administration in Healthy Volunteers | Q60678565 |
| | A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats | Q60695447 |
| | Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers | Q61570355 |
| | The management of cancer pain | Q67653977 |
| | Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs | Q67903664 |
| | Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat | Q68129873 |
| | Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons | Q68182979 |
| | Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations | Q68443393 |
| | Influence of age and disease state in nonsteroidal antiinflammatory drug associated gastric bleeding | Q68453114 |
| | Do the pharmacodynamics of the nonsteroidal anti-inflammatory drugs suggest a role in the management of postoperative pain? | Q35170409 |
| | Potential Renal, Haematological and Allergic Adverse Effects Associated with Nonsteroidal Anti-Inflammatory Drugs | Q35170419 |
| | Differential analgesic effects of aspirin-like drugs | Q35170454 |
| | Worldwide safety experience with nabumetone | Q35639691 |
| | Comprehensive and multidimensional assessment and measurement of pain | Q36296470 |
| | Non-steroidal anti-inflammatory drug-induced gastroduodenal injury: therapeutic recommendations | Q36517019 |
| | Paediatric analgesia. Which drug? Which dose? | Q36636771 |
| | Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy | Q36660298 |
| | An updated safety profile of etodolac in several thousand patients | Q37860957 |
| | Nonsteroidal antiinflammatory drugs. Renal toxicity. Review of pediatric issues | Q38137452 |
| | Opioid responsiveness | Q39459471 |
| | Pharmacokinetics of opioids in renal dysfunction | Q39460590 |
| | Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies | Q39485183 |
| | Pain and its treatment in outpatients with metastatic cancer | Q39485856 |
| | Comparison of morphine and sublingual buprenorphine following abdominal surgery | Q39553572 |
| | Age and morphine analgesia in cancer patients with postoperative pain | Q39569767 |
| | The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients | Q39654047 |
| | Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response | Q39683632 |
| | Renal syndromes associated with nonsteroidal antiinflammatory drugs | Q40168640 |
| | Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. | Q40385238 |
| | Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy | Q40395486 |
| | Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. | Q40447117 |
| | Non-steroidal anti-inflammatory drugs and spinal nociceptive processing | Q40591639 |
| | Adverse reactions to acetaminophen, ASA, and NSAIDs in children: what alternatives? | Q40645864 |
| | The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases | Q40723418 |
| | Hepatic toxicity of antirheumatic drugs | Q40804142 |
| | Gastrointestinal toxicity of newer NSAIDs | Q40841245 |
| | Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. | Q40910814 |
| | Pain assessment in the elderly | Q41025295 |
| | Pharmacological considerations for the pediatric patient | Q41136094 |
| | Opioid analgesic drugs in the elderly | Q41149374 |
| | Central analgesic effect of ketoprofen in humans: electrophysiological evidence for a supraspinal mechanism in a double-blind and cross-over study | Q41323889 |
| | Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years | Q41354684 |
| | Bleeding esophageal ulcers caused by NSAIDs | Q41382761 |
| | Toxicity of Nonsteroidal Anti-Inflammatory Drugs in the Elderly: Is Advanced Age a Risk Factor? | Q41526041 |
| | Mechanism of action of aspirin-like drugs | Q41528610 |
| | Differentiating among nonsteroidal antiinflammatory drugsby pharmacokinetic and pharmacodynamic profiles | Q41528637 |
| | Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis | Q41625132 |
| | Effects of NSAIDs on the kidney | Q41655350 |
| | NSAIDs and increased blood pressure. What is the clinical significance? | Q41657126 |
| | Relationship between nonsteroidal anti-inflammatory drug use, Helicobacter pylori, and gastroduodenal mucosal injury | Q41658624 |
| | Nonsteroidal anti-inflammatory drugs and necrotising fasciitis. An update | Q41682182 |
| | NSAIDs and blood pressure. Clinical importance for older patients | Q41702946 |
| | Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children | Q41704347 |
| | The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers | Q41854197 |
| | Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation | Q41980769 |
| | Metabolism of narcotics | Q42997125 |
| | Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study | Q43497777 |
| | The relative toxicity of nonsteroidal antiinflammatory drugs | Q44117748 |
| | Morphine-3-glucuronide--a potent antagonist of morphine analgesia | Q44142095 |
| | Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain | Q44338649 |
| | Fedotozine reverses ileus induced by surgery or peritonitis: action at peripheral kappa-opioid receptors. | Q44339802 |
| | Relationship between behavioral and physiological indicators of pain, critical care patients' self-reports of pain, and opioid administration | Q44346439 |
| | Impact of environmental and genetic factors on codeine analgesia | Q44856527 |
| | Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition | Q46223466 |
| P433 | issue | 6 | |
| P304 | page(s) | 457-472 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity | |
| P478 | volume | 18 | |